ME Therapeutics Holdings Inc.
METXF
$2.95
$0.000.00%
| Weiss Ratings | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.95 | |||
| 52-Week Low Price | $2.95 | |||
| 52-Week Low Price (Date) | Jul 12, 2024 | |||
| 52-Week High Price (Date) | Jul 12, 2024 | |||
| Valuation | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 192.46M | |||
| Enterprise Value | 191.61M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.04 | |||
| Earnings Per Share Growth | -87.87% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 78.39 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $2.95 | |||
| Enterprise Value/EBITDA (TTM) | -75.57 | |||
| Enterprise Value/EBIT | -75.50 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 25.19M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 236-516-7714 | |||
| Address | 177 Robson Street Vancouver, BC V6B 0N3 | |||
| Website | www.metherapeutics.com | |||
| Country | Canada | |||
| Year Founded | 2014 | |||
| Profitability | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -82.51% | |||
| Return on Equity | -- | |||
| Income Statement | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -963.10K | |||
| EBIT (TTM) | -964.00K | |||
| Net Income (TTM) | -917.80K | |||
| Net Income Avl. to Common (TTM) | -917.80K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 12.81% | |||
| EPS Diluted (TTM) | -0.04 | |||
| EPS Diluted Growth (Q YOY) | 18.69% | |||
| Balance Sheet | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 946.60K | |||
| Cash Per Share (Q) | $0.04 | |||
| Total Current Assets (Q) | 1.03M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 947.10K | |||
| Current Ratio (Q) | 8.181 | |||
| Book Value Per Share (Q) | $0.04 | |||
| Total Assets (Q) | 1.11M | |||
| Total Current Liabilities (Q) | 125.40K | |||
| Total Debt (Q) | 79.00K | |||
| Total Liabilities (Q) | 166.40K | |||
| Total Common Equity (Q) | 947.10K | |||
| Cash Flow | METXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -14.30K | |||
| Cash from Financing (TTM) | 1.11M | |||
| Net Change in Cash (TTM) | 704.90K | |||
| Levered Free Cash Flow (TTM) | -66.70K | |||
| Cash from Operations (TTM) | -394.20K | |||
